**Study Overview**: This study is researching a treatment for Geographic Atrophy (GA), a condition affecting the central part of the retina in the eye, leading to vision loss. The study will test a new treatment called APL-3007, combined with an existing treatment, Syfovre/Pegcetacoplan (APL-2). Participants must have GA due to Age-Related Macular Degeneration (AMD). **Eligibility**: To join, you must be 60 years or older and have GA in one or both eyes. You should have had previous treatment with Syfovre for at least six months. You must also be vaccinated against certain infections like pneumonia and meningitis before starting the study. Certain medical conditions and recent use of other treatments may disqualify you. **Key Points**: - The study is **randomized and placebo-controlled**, meaning some participants will receive the real treatment while others receive a placebo (fake treatment) without knowing which they are getting. - Participants should expect to make **frequent visits** to the study center for treatments and check-ups. - There are **risks** involved, including potential side effects of the treatment.